In colorectal cancer patients, it has been shown that activating mutations of KRAS – an EGFR downstream effector - predicts resistance to anti-EGFR monoclonal antibodies therapy in metastatic patients [23, 24]. The gene discussed is EGFR; the disease is colorectal cancer.